Stocktoria
PROKIDNEY CORP. PROK
PROKIDNEY CORP. (PROK) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $893,000 at a -7725.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| CRDF | Cardiff Oncology, Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
About PROKIDNEY CORP.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
FAQ
Is PROK financially healthy?
PROKIDNEY CORP.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does PROK pay a dividend?
No, PROKIDNEY CORP. does not currently pay a dividend.
How profitable is PROK?
In FY2025, PROKIDNEY CORP. had a net margin of -7725.2%.
What is the analyst price target for PROK?
The average Wall-Street price target for PROKIDNEY CORP. is $6.25, about 322.3% above the recent price, from 6 analysts.
Is PROK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PROKIDNEY CORP.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.